Chong Boon

🎁

[Raghav Sundar @sundar__raghav]

The controversy continues. We just published in @JAMAOnc an analysis showing minimum benefit of immunotherapy for low PD-L1 expressing esophageal tumors https://t.co/3YL4jfW3mE, @FengWan25720657 shows the opposite https://t.co/yjcsd1HeQc. are we none the wiser? @FilippoPietran4

[Nature Reviews Endocrinology @NatureRevEndo]

New content online: The burden and risks of emerging complications of diabetes mellitus https://t.co/mWcYa7TsKz

[Joseph J Zhao @josephjzhao]

Octyl cyanoacrylate skin adhesive with or without subcuticular suture for skin closure after implantable venous port placement for oncology patients: a propensity-score matching analysis
https://t.co/n97Uz1BWif

[Raghav Sundar @sundar__raghav]

https://t.co/2IaMIf0Rrs
Does choice of PD-L1 assay matter? Using multiplex ihc @JoeYeong, we stain the *same* slide for the 22C3 and 28-8 assay showing distinctly different uptake patterns. Check out the poster at @ASCO 2022 and joint publication in Gastric Cancer Journal today!

[Raghav Sundar @sundar__raghav]

https://t.co/LY4gze5ug4
The peritoneum is an immunoprivileged niche, leading to resistance to therapy. In this review in @JCO_ASCO, we describe the biological hallmarks of gastric cancer peritoneal metastases and novel therapeutic approaches to this unique biological entity.

[Raghav Sundar @sundar__raghav]

https://t.co/q9piLsrUA0
Personalizing cancer treatment doses using individual patient data points and Artificial Intelligence. Using the https://t.co/TQRzid6q6o platform with @thedeanh and @AgataBlasiak we report first data from our PRECISE.CURATE trial today at @ASCO AM.

[Ryan Yong Kiat Tay @RyanYKTay]

Does the choice of PD-L1 IHC assay affect immunotherapy eligibility in patients with gastric cancer?

Our study found discordance between assays, with PD-L1 scores and positivity rates on the 28-8 assay being nearly twice of the 22C3 assay - suggesting a need for harmonisation.

[ASCO @ASCO]

#ASCO22 News: Significant discrepancies found among PD-L1 assays used in #GastricCancer in KEYNOTE-811 & CheckMate-649 confirmed in research from @NUSingapore, highlighting that these assays aren't interchangeable in practice. https://t.co/KOSqvrZrpO #ASCODailyNews #gicsm

[Joseph J Zhao @josephjzhao]

@Nicholas_Syn @BenjaminKJTan @TeoChongBoon @dominicyap_ @sundar__raghav
https://t.co/h1W4c0j92v

[Raghav Sundar @sundar__raghav]

Pleased to share our study, just published in the BMJ where we study the efficacy of COVID-19 vaccines in immunocompromised people, including cancer and transplant patients. A third/booster dose appears to be needed in most. https://t.co/dPzK0UYbSq

[Joseph J Zhao @josephjzhao]

😊🎉 @sundar__raghav @LizzySmyth1 @dominicyap_ @TeoChongBoon @yysoon01 @BenjaminKJTan @Nicholas_Syn @NUSMedicine